S&P TSX Capped Composite...

US Dollar vs CAD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ATOS Atossa Therapeutics Inc

1.66

0.14 (9.21%)

May 03 2024 - Closed

Delayed by 15 minutes

High volatility in Atossa Genetics Inc. stock price on Wednesday which ended trading at $7.15

The Atossa Genetics Inc. stock price gained 1.85% on the last trading day (Wednesday, 23rd Jun 2021)... View Full Article on StockInvest.us

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024

Click Here for more Atossa Therapeutics Charts.

Atossa Therapeutics Inc News

Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen
Monday 29 April 2024 (6 days ago) • GlobeNewswire Inc.

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer
Monday 15 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference
Thursday 11 April 2024 (3 weeks ago) • GlobeNewswire Inc.

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Tuesday 9 April 2024 (4 weeks ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update
Monday 1 April 2024 (1 month ago) • GlobeNewswire Inc.

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient
Tuesday 19 March 2024 (2 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements
Monday 18 March 2024 (2 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors
Tuesday 12 March 2024 (2 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study
Thursday 22 February 2024 (2 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial
Wednesday 7 February 2024 (3 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Issues Letter to Shareholders
Tuesday 9 January 2024 (4 months ago) • GlobeNewswire Inc.

Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director
Monday 4 December 2023 (5 months ago) • GlobeNewswire Inc.

More Atossa Therapeutics Inc News Articles

Code Green Apparel (PK)

Voip Pal Com (QB)

Kraig Biocraft Laborator... (QB)

Cann American (CE)

Hannover House (PK)

AMC Entertainment

Trump Media and Technology

1812 Brewing (PK)

Rennova Health (PK)

Anavex Life Sciences

Digital Brand Media and ... (PK)

Northwest Biotherapeutics (QB)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions